Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹3,869 Cr
Revenue (TTM)
₹653 Cr
Net Profit (TTM)
₹183 Cr
ROE
25.7 %
ROCE
35 %
P/E Ratio
21.1
P/B Ratio
7.3
Industry P/E
38.04
EV/EBITDA
21.6
Div. Yield
1 %
Debt to Equity
0
Book Value
₹320.8
EPS
₹57.6
Face value
8
Shares outstanding
16,539,015
CFO
₹457.00 Cr
EBITDA
₹581.43 Cr
Net Profit
₹324.76 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
| 7.2 | 12.0 | 12.3 | 50.6 | 66.0 | 55.0 | 30.9 |
|
BSE Healthcare
| -2.6 | 5.8 | 11.7 | 19.7 | 25.9 | 22.2 | 11.0 |
|
BSE Small Cap
| -2.6 | 9.6 | 21.0 | 6.2 | 27.3 | 35.1 | 17.6 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
| 63.9 | 57.7 | 37.0 | 64.6 | 15.8 | 30.6 | -51.3 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
|
2,341.5 | 3,869.3 | 653.4 | 183.2 | 21.2 | 20.9 | 21.1 | 7.3 |
| 463.8 | 4,234.9 | 2,387.0 | 168.1 | 9.7 | 12.7 | 25.2 | 3.1 | |
| 334.6 | 3,636.7 | 150.8 | 48.8 | 42.1 | 20.7 | 74.6 | 14.6 | |
| 280.7 | 2,607.9 | 1,664.9 | -77.9 | -0.9 | -7.1 | -- | 2.6 | |
| 88.8 | 2,592.4 | 2,079.2 | 101.1 | 6.3 | 6 | 25.6 | 1.5 | |
| 64.7 | 3,537.6 | 1,811.6 | 118.0 | 8.0 | 10.4 | 30 | 3.1 | |
| 714.1 | 3,620.6 | 921.9 | 95.8 | 9.0 | 8 | 36.3 | 2.9 | |
| 505.2 | 2,436.1 | 1,283.8 | 0.5 | 8.3 | 0 | -- | 2.2 | |
| 236.0 | 5,138.9 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 46.7 | |
| 606.1 | 4,280.0 | 2,028.9 | 150.6 | 7.5 | 6.2 | 31.1 | 1.8 |
No Review & Analysis are available.
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs... in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology, cardiovascular, pediatrics, neurology, anti-dengue, and dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust. Read more
Incorporated
2007
Chairman
Harsh Goenka
Managing Director
Ashok Nair
Group
RPG Enterprises
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of RPG Life Sciences Ltd stood at ₹ 658 Cr as on 31-Mar-25
The share price of RPG Life Sciences Ltd is ₹2,341.50 (NSE) and ₹2,339.50 (BSE) as of 13-Jun-2025 IST. RPG Life Sciences Ltd has given a return of 66.02% in the last 3 years.
RPG Life Sciences Ltd has a market capitalisation of ₹ 3,869 Cr as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of RPG Life Sciences Ltd is 7.29 times as on 13-Jun-2025, a 119% premium to its peers’ median range of 3.33 times.
The P/E ratio of RPG Life Sciences Ltd is 21.12 times as on 13-Jun-2025, a 44% discount to its peers’ median range of 38.04 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the RPG Life Sciences Ltd and enter the required number of quantities and click on buy to purchase the shares of RPG Life Sciences Ltd.
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology, cardiovascular, pediatrics, neurology, anti-dengue, and dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
The prominent promoters of RPG Life Sciences Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Nucleus Life Trust (Mr. Harsh Vardhan Goenka is a Trustee) |
53.94%
|
|
Ektara Enterprises Llp |
15.57%
|
|
Stel Holdings Limited |
3.18%
|
The chairman of the company is Harsh Goenka, and the managing director is Ashok Nair.
There is no promoter pledging in RPG Life Sciences Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
5,139
|
|
|
4,280
|
|
|
4,235
|
|
|
3,637
|
|
|
3,621
|
|
|
3,538
|
|
|
2,608
|
|
|
2,592
|
|
|
2,436
|
| RPG Life Sciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
20.93
|
|
Operating margin(%)
|
21.15
|
|
Net Margin(%)
|
27.51
|
|
Dividend yield(%)
|
1.03
|
Yes, TTM profit after tax of RPG Life Sciences Ltd was ₹183 Cr.
₹96.20
(
